Intellectual Disability and Psychotropic Medications

被引:2
|
作者
Herzig, Lisa [1 ]
de Lacy, Nina [2 ]
Capone, George [3 ]
Radesky, Jenny [4 ]
机构
[1] Seattle Childrens Hosp, Div Dev Pediat, Seattle, WA 98105 USA
[2] Seattle Childrens Hosp, Div Psychiat & Behav Med, Seattle, WA USA
[3] Kennedy Krieger Inst, Down Syndrome Clin & Res Ctr, Baltimore, MD USA
[4] Univ Michigan, Med Sch, Div Dev Behav Pediat, Ann Arbor, MI 48109 USA
关键词
trisomy; 21; intellectual disability; psychotropic medication; self-injury; ANTIPSYCHOTIC USE; DOWN-SYNDROME; CHILDREN;
D O I
10.1097/DBP.0000000000000613
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
CASE: Andrew is a 17-year-old male with trisomy 21, commonly known as Down syndrome, and accompanying severe intellectual disability who presents to your primary care office with his father for the first time to establish care and assistance with transition. Andrew has a history of a complete atrioventricular canal that was repaired as an infant and poorly controlled infantile spasms. Currently, he struggles with constipation, esophageal strictures, medullary nephrocalcinosis, urinary retention, sleep dysregulation, G-tube dependency, and hip dysplasia. Andrew walked at 11 to 12 years of age. Currently, he ambulates on his feet at home and in a wheelchair out in the community. He is nonverbal but can imprecisely sign for "more" and understands a few words. His father reports that his main concern is long-standing nonsuicidal self-injury (NSSI) and aggression. His self-injury consists of head banging against hard objects such as concrete floors and biting or scratching himself to the point of bleeding. Over the past 13 years, he has been prescribed over 10 different psychotropic medications, including various typical and atypical antipsychotics, selective serotonin reuptake inhibitors, benzodiazepines, mood stabilizers, and alpha agonists, all of which were discontinued because of the perception of undesirable side effects or lack of efficacy. His current medications include aripiprazole, olanzapine, levetiracetam, clorazepate, and trazodone. To rule out causes of irritability, you order a brain and spine magnetic resonance imaging, metabolic testing (for causes of NSSI such as Lesch-Nyhan), an autoimmune workup (for causes of pain or inflammation such as juvenile idiopathic arthritis), and hearing/vision testing, which are all normal. Previous testing by subspecialists (he is followed by gastroenterology, sleep medicine, orthopedics, nephrology, neurology, cardiology, and psychiatry) included normal renal ultrasound and no clear sources of gastrointestinal pain. However, key providers are spread among multiple institutions and do not regularly communicate. Andrew lives with his parents, who are highly educated and very dedicated to his health and wellness. His mother travels frequently for work, and his father is Andrew's full-time caregiver. Despite remaining ostensibly positive, his father reports significant caregiver burnout and fatigue. Over the next several months, Andrew continues to experience worsening NSSI necessitating medication changes despite active involvement in applied behavior analysis therapy. During this time, he presents to the emergency department multiple times for irritability and self-injury. On examination, he is aggressive, irritable, has bruises on his forehead and scratches on his skin, and has intermittent vertical gaze deviation that was noticeable to parents. The rest of his physical and neurological examination was unremarkable and revealed no asymmetry, clonus, hyperreflexia, or changes in muscle tone. While examining his extremities, joints, and abdomen, there was no obvious source of pain. What are your next steps? How would you support this family, both in the immediate management of his self-injury and long-term care needs for this medically and behaviorally complex adolescent?
引用
收藏
页码:591 / 593
页数:3
相关论文
共 50 条
  • [31] Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability
    Scheifes, Arlette
    de Jong, Daniel
    Stolker, Joost Jan
    Nijman, Henk L. I.
    Egberts, Toine C. G.
    Heerdink, Eibert R.
    RESEARCH IN DEVELOPMENTAL DISABILITIES, 2013, 34 (10) : 3159 - 3167
  • [32] Psychotropic medication for problem behaviours in intellectual disability and autism spectrum disorder: the need for caution
    Bertelli, Marco O.
    BJPSYCH ADVANCES, 2023, : 334 - 336
  • [33] Dementia in intellectual disability
    Sheehan, Rory
    Ali, Afia
    Hassiotis, Angela
    CURRENT OPINION IN PSYCHIATRY, 2014, 27 (02) : 143 - 148
  • [34] Sexuality and Intellectual Disability
    Wenger, Jodi
    Downes, Alison
    Blum, Nathan
    Augustyn, Marilyn
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2017, 38 (02) : S47 - S48
  • [35] Lithium Treatment Is Safe in Children With Intellectual Disability
    Yuan, Junying
    Song, Juan
    Zhu, Dengna
    Sun, Erliang
    Xia, Lei
    Zhang, Xiaoli
    Gao, Chao
    Agam, Galila
    Wang, Xiaoyang
    Blomgren, Klas
    Zhu, Changlian
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2018, 11
  • [36] The Intersection of Intellectual Disability and Dementia: Report of The International Summit on Intellectual Disability and Dementia
    Watchman, Karen
    Janicki, Matthew P.
    Asante, Cathy
    Berankova, Anna
    Bishop, Kathleen
    Cadovius, Nicole
    Cooper, Sally-Ann
    Coppus, Tonni
    Crowe, Jim
    Dodd, Karen
    Fortea, Juan
    Gaertner, Claudia
    Haksar, Kiran
    Santos, Flavia Heloisa
    Hogan, Mary
    Janicki, Matthew P.
    Jokinen, Nancy
    Keller, Seth
    larsen, FroDe
    Lucchino, Ronald
    McCallion, Philip
    McCarron, Mary
    Mittler, Peter
    Pearson, Jim
    Quinn, Sam
    Rebillat, Anne-Sophie
    Reilly, Evelyn
    Service, Kathy
    Splaine, Michael
    Stemp, Sandy
    Strydom, Andre
    Tiziano, Gomiero
    Udell, Leslie
    Watchman, Karen
    GERONTOLOGIST, 2019, 59 (03) : 411 - 419
  • [37] Constipation prevalence and risk from prescribed medications in people with intellectual disability: Findings from an English mortality programme
    Roberts, Christina
    Ding, Jonathon
    Bishara, Delia
    Riaz, Sahar
    Sheehan, Rory
    White, Adam
    Strydom, Andre
    Chauhan, Umesh
    JOURNAL OF INTELLECTUAL DISABILITIES, 2024,
  • [38] Reducing Psychotropic Medications in an Intensive Residential Treatment Center
    Huefner, Jonathan C.
    Griffith, Annette K.
    Smith, Gail L.
    Vollmer, Dennis G.
    Leslie, Laurel K.
    JOURNAL OF CHILD AND FAMILY STUDIES, 2014, 23 (04) : 675 - 685
  • [39] PARENTAL ATTITUDES TOWARD THE PRESCRIPTION OF PSYCHOTROPIC MEDICATIONS FOR THEIR CHILDREN
    Al-Haidar, Fatima A.
    JOURNAL OF FAMILY AND COMMUNITY MEDICINE, 2008, 15 (01) : 35 - 41
  • [40] Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey
    Perry, B. I.
    Kwok, H. F.
    Mendis, J.
    Purandare, K.
    Wijeratne, A.
    Manjubhashini, S.
    Dasari, M.
    Esan, F.
    Gunaratna, I.
    Naseem, R. A.
    Hoare, S.
    Chester, V.
    Roy, A.
    Devapriam, J.
    Alexander, R.
    Cooray, S. E.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2018, 62 (02) : 140 - 149